Balancing safety and efficacy: tuning the biodistribution and pharmacokinetics of cytokine immunotherapies

This publication has 67 references indexed in Scilit:

• A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors
  BMC Cancer, 2013
• Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
  Cancer Immunology, Immunotherapy, 2012
• The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
  Molecular & Cellular Proteomics, 2012
• High response rate after intratumoral treatment with interleukin‐2
  Cancer, 2010
• A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
  Molecular Cancer Therapeutics, 2009
• Pharmacokinetic and pharmacodynamic study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors
  Gene Therapy, 2007
• Engineered vascular‐targeting antibody‐interferon‐γ fusion protein for cancer therapy
  International Journal of Cancer, 2005
• Treating cancer with PEG Intron
  Cancer, 2002
• Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2
  JNCI: Journal of the National Cancer Institute, 1994
• Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia
  New England Journal of Medicine, 1994